This research study aims to improve care coordination in the context of cancer survivorship care by understanding how primary care providers and cancer specialists share responsibilities. Researchers want to understand how technology can help these teams communicate more clearly and effectively to coordinate care for survivors. The study team will use surveys and conduct interviews and focus groups for interested and eligible participants as methods of data collection to inform the research. Oncologists, primary care physicians, and survivors of breast, prostate, lung, colon and rectal cancer that meet the eligibility criteria will complete surveys and engage in interviews to understand barriers and identify strategies to improve care. Using this information, the team will create an intervention plan called ACT that addresses common barriers, using focus group discussions to refine the intervention. The ultimate goal is to help patients receive better and more coordinated follow‑up care.

This study is for patients that have been diagnosed with locally advanced or metastatic solid tumor, including non-small cell lung cancer (NSCLC), triple-negative breast cancer, gastric cancer, esophageal cancer (or gastroesophageal cancer), head and neck squamous cell cancer, ovarian cancer, endometrial cancer, or cervical cancer. The study is testing and investigational drug called NRM-823. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of this study is to evaluate the safety and tolerability of NRM-823 as monotherapy and in combination with pembrolizumab. The study drug is given as an injection into the stomach (or another place, like the thigh). An injection is like a shot between the skin and muscle so that the drug can enter your body. Participants can expect to be on this study until the first radiographic disease progression.

This study is for patients that have been diagnosed with breast cancer. The purpose of this research is to assess the safety and efficacy of sacituzumab tirumotecan (sac-TMT) in people with certain types of breast cancer who will have surgery to remove their breast cancer. This trial will compare two treatment plans that patients will receive before their surgery. One of these treatment plans will involve patients receiving Sac-TMT and pembrolizumab (pembro), followed by chemotherapy and pembro. Patients enrolled in the other treatment plan will receive chemotherapy and pembro. Patients will be given the drug intravenously (a needle in a vein). Patients may experience a decrease in white blood cells, platelets, and red blood cells (anemia). Patients are expected to remain in the study for a minimum of 30 months or longer. There will be a total of 12 patients locally enrolled.

This study is for adults with invasive breast cancer who are scheduled to have surgery of the breast. The purpose of the study is to determine whether cannabidiol (CBD) helps to slow the growth or cancer cells and whether or not taking CBD during the waiting period before surgery reduces anxiety. Participation in this study will last approximately 56 days.

Half of caregivers in the US are adults caring for a parent, and many of these are young adults, between the ages of 18-35. This presents communication and quality of life challenges for both the young adult child caregiver and parent with cancer; however, this dyad (e.g., two people together) has not been well studied. We will conduct interviews with young adult child caregivers and parents with cancer to learn more about communication challenges and support needs in this dyad. Dyad members will also complete self-report measures asking about mood, coping, communication and quality of life. Findings will inform the development of an intervention to improve dyadic communication and quality of life.

This study is recruiting non-metastatic breast cancer survivors who were diagnosed between ages 18 and 51 and are currently 6 months to 5 years post-treatment. Eligible participants must have a score of 5–14 on the PHQ-8 depression screening tool. This study is testing a digital mindfulness meditation-based program. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Participants will be randomly assigned (like drawing one number out of three at random) to one of three groups: (1) live online mindfulness classes over Zoom, (2) a specially designed mindfulness app, or (3) guided audio meditations. The primary purpose of this study is to determine if different ways of delivering digital mindfulness training can improve mental health and well-being in younger breast cancer survivors. The program is delivered either by live online sessions, through a mobile app, or by listening to guided meditation recordings. Participants can expect to be in this study for about 9 months, including a 6-week training program and questionnaires before, during, and after training. Participants will be enrolled for a duration of 9 months, and a total of 15 patients will be recruited locally over the course of 36 months.

This study is recruiting non-metastatic breast cancer survivors who were diagnosed between ages 18 and 51 and are currently 6 months to 5 years post-treatment. Eligible participants must have a score of 5–14 on the PHQ-8 depression screening tool. This study is testing a digital mindfulness meditation-based program. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Participants will be randomly assigned (like drawing one number out of three at random) to one of three groups: (1) live online mindfulness classes over Zoom, (2) a specially designed mindfulness app, or (3) guided audio meditations. The primary purpose of this study is to determine if different ways of delivering digital mindfulness training can improve mental health and well-being in younger breast cancer survivors. The program is delivered either by live online sessions, through a mobile app, or by listening to guided meditation recordings. Participants can expect to be in this study for about 9 months, including a 6-week training program and questionnaires before, during, and after training. Participants will be enrolled for a duration of 9 months, and a total of 15 patients will be recruited locally over the course of 36 months.

Cancer caregivers in emerging and young adulthood (ages 18-35) are an underresearched and unsupported group of caregivers, and yet they are not uncommon. To address this critical support gap, the goal of this study is to develop and pilot test a caregiving support intervention specifically tailored for emerging and young adults caring for a parent with cancer. This phase of the study is intended to capture feedback on the intervention via focus groups with emerging and young adult caregivers of a parent with cancer.

We will evaluate the ability of a technology-based intervention E-Care to improve communication of information about breast cancer risk and improve discussion about breast cancer screening in the primary care setting. Women ages 25-75 seen by their primary care clinician are potentially eligible to participate. Study activities include completion of a health questionnaire, reviewing a video on breast cancer screening, completion of a post-visit survey, and potential opportunity for a brief interview.

This study is for adult patients with Triple Negative Breast Cancer (TNBC) who are at high risk for cardiotoxicity. The purpose of this study is to evaluate a non-anthracycline-based chemotherapy and immunotherapy regimen to determine if this approach reduces heart-related side effects. Participation will include standard of care visits along with questionnaires and blood draws completed for research purposes. Participation in this study is anticipated to last approximately 6 months with follow up over 2 years.